[Studies on the kinetics of sulfaclomide and the effect of sulfaclomide therapy on p-aminohippuric acid clearance in pregnancy].
After a single oral dose and after 11 day repeated administration of Sulfaclomide elimination half-life of Sulfaclomid was not different in pregnant and in nonpregnant women. The initial serum concentrations of Sulfaclomid are lower in pregnant than in nonpregnant persons. Nearly all Sulfaclomid measurable in serum exists from unchanged sulfonamide. This rate does not change during treatment. By treatment with Sulfaclomid elimination half-life of p-aminohippurate (PAH) is shortened, renal excretion of p-aminohippurate is significant increased.
D000618:Aminohippuric Acids / Q000378:metabolism* / Q000652:urine; D000893:Anti-Inflammatory Agents / Q000378:metabolism* / Q000494:pharmacology; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D011247:Pregnancy; D011743:Pyrimidines / Q000494:pharmacology; D013424:Sulfanilamides / Q000494:pharmacology*
D000618:Aminohippuric Acids; D000893:Anti-Inflammatory Agents; D011743:Pyrimidines; D013424:Sulfanilamides
Untersuchungen zur Kinetik von Sulfaclomid und der Einfluss der Sulfaclomidtherapie auf die p-Aminohippursäure-Clearance in der Schwángerschaft